Skip to main content
Premium Trial:

Request an Annual Quote

Olympus, Cangen to Co-develop Hybrid DNA/Protein Microarray-based Test for Lung Cancer

NEW YORK, May 25 (GenomeWeb News) - Cangen Biotechnologies and Olympus plan to co-develop a hybrid DNA- and protein-based diagnostic that can detect early-stage lung cancer, the firms said today.

 

The alliance will provide Cangen access to Olympus' microarray technology to enable the DNA-based portion of the test. Terms also call for Olympus to "refine" and "further develop" its microarray technology to help Cangen develop the hybrid test. Technical details were not disclosed.

 

"This collaboration complements development efforts for our microarray technology and affords us the opportunity to commercialize that technology," Hiroyuki Yoshimori, division manager of Biomedical Business Incubation Division in Olympus, said in a statement.
 
Financial terms were not released.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.